Navigating the GLP-1 Boom: Clinical Strategy and Industry Insights

The biopharmaceutical industry is undergoing a structural realignment that will directly shape clinical practice, formulary designs, and treatment paradigms for years to come. Deloitte’s 16th annual report, “Navigating the GLP-1 boom: Measuring the return from pharmaceutical innovation,” highlights an industry at a historic inflection point.

On the surface, pharmaceutical research and development (R&D) is showing strong signs of recovery. The projected internal rate of return (IRR) on late-stage pipeline assets rose for the third consecutive year, reaching 7.0% in 2025—a notable 1.1 percentage point increase from 2024. However, this apparent health is an illusion driven by a narrow segment of therapeutic breakthroughs.

The recovery is powered almost entirely by a small number of mega-blockbuster programs, specifically glucagonlike peptide-1 receptor agonists (GLP-1s) and GLP-1 combinations with gastric inhibitory polypeptide-based drugs (GIPs) targeting obesity. Strip away these mechanisms, and the underlying health of industry R&D productivity collapses to an IRR of just 2.9%. For frontline healthcare providers, clinical executives, and formulary managers, understanding this seismic shift is not merely an academic exercise—it is essential for navigating the future of medicine.

Why it Matters

The Structural Illusion and Portfolio Fragility

This report matters intensely to healthcare providers because the commercial drivers of pharmaceutical innovation dictate which therapies make it out of clinical trials and onto clinical clipboards. The core finding, that a handful of GLP-1 and GIP assets are masking broader industry stagnation, exposes an unprecedented level of portfolio concentration. For the first time in the 16-year history of this analysis, obesity has displaced oncology as the absolute largest contributor to late-stage pipeline value. Obesity assets now account for roughly 25% of all forecast commercial inflows from the 2025 late-stage pipeline, a staggering leap from a mere 1% contribution in 2022.

This high degree of concentration creates a hyper-competitive, high-stakes environment where pharmaceutical pipelines are highly sensitive to therapeutic area-specific shocks. If the GLP-1/GIP space experiences unexpected long-term safety signals, tightening of regulatory oversight, aggressive payer pushback on market access, or prolonged manufacturing supply constraints, the overall financial health of the pharmaceutical sector could suffer a major contraction. For providers, this structural instability means that a single clinical or regulatory failure could dismantle a manufacturer’s pipeline, abruptly halting the development of adjacent therapies.

Escalating Financial Pressure

Furthermore, the economic reality of developing new drugs is growing more severe. The average cost to progress an asset from discovery to launch has surged to $2,671 million in 2025, up from $2,229 million in 2024. This inflation is driven by rising baseline R&D expenditures (experienced by 17 out of 20 analyzed companies), coupled with a 4.6% decline in the total number of late-stage assets. Because development is more expensive and spread across fewer drugs, manufacturers face massive pressure to extract high margins from their successful launches. Clinicians can expect that newly approved therapies will enter the market with premium pricing models designed to counteract these astronomical development costs.

Systemic Risk

For the first time in 16 years, obesity has displaced oncology as the dominant value driver in late-stage pipelines (commanding 24.7% of total forecast value). This concentration leaves the entire industry highly vulnerable to sector-specific shocks like safety signals, regulatory changes, or manufacturing constraints.

Who is Affected

Payer Pressure, Specialty Consolidation, and Patient Segments

The ripple effects of this GLP-1 and GIP centralization impact multiple stakeholders across the care delivery spectrum, shifting the operational landscape for clinicians, payers, and patients alike.

Primary Care and Specialized Providers

Primary care physicians, endocrinologists, cardiologists, and gastroenterologists are finding themselves on the front lines of an expanding clinical frontier. While GLP-1/GIP assets primarily target obesity and diabetes, their late-stage pipelines are aggressively expanding into a broad scope of companion indications, including chronic heart failure, osteoarthritis, and liver fibrosis (such as MASH/NASH). Specialized clinicians must prepare for a flood of multi-indication metabolic drugs that cross traditional clinical boundaries. This requires deeper cross-specialty coordination and a comprehensive approach to managing metabolic health rather than treating isolated symptoms. All of these different specialties will need to coordinate care for their patients using a unified metabolic care continuum model.

Payer Organizations and Formulary Committees

Payer networks and institutional formulary committees are facing severe budgetary strains. The Deloitte data notes that portfolio value is increasingly concentrated in a small number of mechanism-of-action (MoA) tiers. In 2025, just 54 blockbuster asset-indications, representing a tiny 9% of the late-stage cohort, are projected to generate roughly 70% of total risk-adjusted peak sales. Payer organizations will continue to respond to this high concentration by implementing strict utilization management strategies, such as rigorous prior authorization requirements, step-therapy protocols, and narrow definitions of medical necessity, to manage the financial impact of these high-cost therapies. Formulary committees will need to analyze real-world data (RWD) turned evidence (RWE) to assist with formulary decisions.

The Pharmaceutical Industrial Complex

The concentration of value extends deep within the pharmaceutical landscape itself. Within any given therapeutic category, a small handful of companies dominate the landscape: the assets of the top three companies in any given therapy area account for over 50% of its projected value. In obesity, the top three control an astonishing 95.8% of the value pipeline. Even in oncology, where 17 of the 20 cohort companies compete, the top three control 50.8% of the value. This means that a few massive entities dictate clinical research priorities and market availability, leaving smaller biotech firms to struggle for visibility or face acquisition.

What Changes

What the research says

Based on the data within the report, the pharmaceutical industry has reached a historic inflection point. While the headline late-stage pipeline internal rate of return (IRR) improved to 7.0% in 2025, this apparent health is an illusion. The recovery is driven entirely by a few mega-blockbuster GLP-1 and GLP-1/GIP assets. Stripping away these mechanisms reveals an underlying industry IRR of just 2.9%.

This matters because obesity has displaced oncology as the largest contributor to pipeline value, accounting for 24.7% of total forecast sales. This hyper-concentration exposes portfolios to severe therapeutic-area-specific shocks, such as manufacturing or regulatory hurdles.

Those affected span the entire healthcare ecosystem. The concentration is highly monopolized: the top three companies control 95.8% of the obesity pipeline value. Furthermore, GLP-1 applications are expanding rapidly into multi-specialty companion indications like chronic heart failure and liver fibrosis.

What changes is the foundational toolkit of medicine. Driven by the metabolic boom, large molecules now command 55% of pipeline volume and 64% of projected value. Moving forward, clinicians must adapt to sophisticated patient segmentation and navigate aggressive payer constraints as manufacturers face rising development costs of $2,671 million per asset.

The Clinical Environment and Portfolio Priorities

The systemic trends identified by Deloitte point toward several definitive shifts in the clinical and operational realities that healthcare providers must navigate moving forward.

The “Long Tail” Scrutiny of Specialized Therapeutics

While mega-blockbusters capture headlines, a “long tail” of assets persists: approximately 53% of pipeline asset-indications have a forecast peak sales potential below $250 million. In an industry facing rising costs, manufacturers are ruthlessly auditing these lower-return portfolios. Providers should expect drug developers to divest or abandon assets that do not offer a clear “first-in-class” or “best-in-class” clinical advantage. Rare diseases remain a steady priority, maintaining a 36% volume share of the pipeline, but any asset outside of metabolic or orphan disease spaces will face intense hurdles to secure funding, potentially slowing innovation in less profitable specialties.

A Shift Toward Large Molecules and Novel MoAs

The therapeutic toolkit itself is fundamentally changing. The trend toward large molecules (such as monoclonal antibodies and protein therapeutics) continues to accelerate rapidly. In 2025, large molecules accounted for 55% of late-stage pipeline assets and are projected to generate 64% of total value—a huge increase from 44% value share in 2024. Conversely, traditional small molecule therapies have plummeted, dropping to 29% of projected value from 46% the previous year. Furthermore, the value share of assets with a novel MoA (defined as late-stage mechanisms never previously launched) surged to 53% in 2025. Clinicians must prepare for a practice environment dominated by complex biologics and net-new mechanisms, requiring advanced education around administration, immunogenicity, and specialized storage infrastructures.

Required Sophistication in Patient Segmentation

Because the commercial space for obesity and metabolic therapies is highly competitive, manufacturers will pivot from broad-spectrum marketing to highly sophisticated patient segmentation. Clinical trials will increasingly look at specific sub-populations and phenotypic variations across reimbursed and direct-to-consumer (DTC) markets. Healthcare providers will need to become equally sophisticated, moving past generic body mass index (BMI) thresholds to evaluate patient eligibility using precise biomarkers, genetic predispositions, and comorbidity profiles. This ensures that these high-cost, high-impact therapeutics are directed to patients who will derive the greatest clinical benefit.

Key Takeaways

1. Formulary Agility: Anticipate heavy payer constraints and prepare clinical data workflows to efficiently justify long-term metabolic treatments.
2. Biologics Readiness: Upgrade clinical workflows to support large-molecule biologics, which now represent nearly two-thirds of pipeline value.
3. Precision Medicine: Adopt sophisticated patient segmentation models to align clinical prescribing habits with highly targeted novel mechanisms coming to market.

Ultimately, the GLP-1 boom is a double-edged sword. It brings an unprecedented wave of innovative therapies to tackle some of the most pervasive chronic diseases of our time. Yet, it strains the underlying infrastructure of pharmaceutical innovation, leaving health systems vulnerable to narrow market failures and premium pricing pressures. By understanding that current R&D metrics are heavily skewed by metabolic blockbusters, healthcare providers can proactively adapt their organizational, formulary, and clinical strategies to thrive in a highly concentrated medical landscape.

Reference

1. https://www.deloitte.com/us/en/industries/life-sciences-health-care/perspectives/navigating-the-glp-boom.html